Dianthus CFO Sells 20,000 Shares for $903,600 After Massive Year-End Run

Core Insights - The transaction indicates a complete disposition of direct equity holdings by Savitz Ryan, resulting in zero remaining directly held shares for future sales unless additional equity is acquired or more options are exercised [1][4]. Company Overview - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing monoclonal antibody therapies for severe autoimmune and inflammatory conditions, including diseases like generalized myasthenia gravis and multifocal motor neuropathy [6]. Transaction Details - On December 4, 2025, Savitz Ryan, CFO & CBO of Dianthus Therapeutics, exercised 20,000 stock options and sold the shares for a total of $903,600, at a weighted average price of $45.18 per share [4][5]. - The transaction was executed entirely through direct holdings, with no participation from indirect entities such as trusts or LLCs [2][5]. Market Context - Dianthus Therapeutics experienced significant gains after issuing 7.6 million shares at $33 per share, raising $288 million for development activities, and reported promising clinical trial results in its third-quarter earnings [9]. - The stock price has retreated from its high but remains around $38, with analysts estimating a one-year target of $63 [9].